ORGANIZATION

Biotechnology Innovation Organization

trade association · DC

Website ↗← Back to organizations

35LDA FILINGS

76LOBBYISTS

0FLY-INS

Federal Lobbying Spend

$8.7M

Total LDA-disclosed spend (in-house + retained) across all reported periods.

Most recent LDA filing posted April 2026.

Likely Asks (from LD-2 filings)

reauthorizeof the Pandemic and All Hazards Preparedness Act×4

Topics in Filings

514

Policy topics named in LD-2 filings. This org's filings are topical rather than positional — these are the issues it's actively lobbying on, even without a stated verb of position.

Medical Countermeasure Priority Review Voucher Reauthorization×146

CMMI: GLOBE and GUARD Models×112

ORPHAN Cures Act×100

Interagency Patent Coordination and Improvement Act×93

Preserve Access to Affordable Generics and Biosimilars Act×91

Prescription Pricing for the People Act×89

National Coverage Determination×87

Antimicrobial Resistance×86

International Pricing Policies×84

R&D Funding for Medical Countermeasures×79

Lowering Drug Costs for American Families Act×77

CMMI Authority×72

Show all 514 topics (+502 more) ▾

Development and Procurement×72

Pharmacy Benefit Manager Transparency Act×72

Funding for Strategic National Stockpile×71

Most Favored Nation Drug Pricing Proposals×71

Stop STALLING Act×71

Pandemic Preparedness×70

Biodefense/Biomedical/Emergency Preparedness Research×68

FY 2026 Appropriations for Agencies×68

Centers for Disease Control and Prevention×67

FY 2026 Appropriations for Specific Issues×67

Health Resources and Services Administration×67

HHS Office of Infectious Disease and HIV/AIDS Policy×65

Big Savings Act×58

Pediatric Priority Review Voucher×57

340B Rebate Rule×56

Administration for Strategic Preparedness and Response×56

Biomedical Advanced Research and Development Authority×56

Maintaining Investments and New Innovation×56

Development and Procurement Issues×54

Give Kids a Chance Act×54

Drug Supply Chain Management×52

Supply Chain Issues×52

Clinical Trial Data in China×51

Vaccines and Infectious Diseases×51

Drug Pricing×50

MCM PRV Reauthorization×43

Data Privacy Working Group Draft×42

Food & Drug Administration×42

Restrictions on Intellectual Property Rights×42

FY 2025 Appropriations×41

General issues×41

Vaccine Injury Compensation Program×40

Affordable Prescriptions for Patients Act×38

Domestic Manufacturing×38

Healthcare and Biotechnology×38

Risky Research Review Act×37

Adult Immunization×36

Advanced Manufacturing×36

Alternative Payment Arrangements for Gene Therapies×36

Drug Benefit Design×36

Drug Shortages×36

National Defense Authorization Act×36

Patient Cost-Sharing and Implementation×36

Quality & Distribution×36

Supply Chain Integrity and Traceability×36

Vaccine Safety net and Vaccine Infrastructure×36

Value of Vaccines and Vaccine Confidence×36

MCM Manufacturing & Capacity×35

Orphan Drug Tax Credit×35

Pricing and Rebates×35

Vaccine Injury Compensation Modernization×35

Alternative Funding Programs×34

Average Manufacturer Price Calculations×34

Biosimilar Red Tape Elimination Act×34

Let Injured Americans Be Legally Empowered×34

SAFE STEP Act×34

Support of Patient Premiums and Cost-Sharing Obligations×34

Vaccine Access Improvement Act×34

Funding for Women's Health Research×33

Medicare Drug Price Negotiation Act×33

Modernizing and Ensuring PBM Accountability×33

Medicaid VBPs for Patients×32

Value-based Contracting and Communications×32

FY 2026 Appropriations×31

Increasing Transparency in Generic Drug Application×31

Rare Pediatric Disease Priority Review Voucher Program reauthorization×31

IRA implementation. 340B×30

Orphan drugs×30

Pandemic Preparedness -R&D Funding for Medical Countermeasures×30

Supply chain×30

Vaccine policy×30

Biosecurity Modernization×29

Non-Opioid Analgesics Orphan Drug Issues×29

Biosimilars Competition×28

Centers for Medicare and Medicaid×28

CMMI×28

Funding for Section 317×28

National Defense Authorization Act 2027×28

National Institutes of Health×28

Pediatric Priority Review Voucher Pandemic Preparedness×28

Small Business Innovation and Economic Security Act×28

Bio COMPETES×27

BIOSECURE Act×27

Value-Based Purchasing×24

Affecting innovation, including vaccines×23

FDA, genetic engineering, and regulations×23

Impacting patient access to treatments×23

Items related to USDA×23

Legislative and regulatory issues×23

Medicare Part B coverage and reimbursement issues×23

Public health issues×23

Updates and reforms×23

Executive Order on Access to Affordable Life-Saving Medications×22

Found in H.R. 1, the One Big Beautiful Bill Act×22

House GOP RFI on Supply Chain×22

Strengthening Innovation in Medicare and Medicaid Act×22

American Innovation and Jobs Act×21

Biosimilar Copay×21

China Biotechnology Regulations×21

Helping Startups Continue to Grow Act×21

Interchangeability and Pharmacy Substitution×21

Mandating Exclusive Review of Individual Treatments×21

Maternal Immunization×21

Medicare Part B Physician-Administered Products×21

Medication Affordability and Patient Integrity Act×21

Most Favored Nation×21

One Big Beautiful Bill Act×21

Program Implementation & Oversight×21

Promising Pathway Act×21

Advanced Research Projects Agency for Health×20

American Privacy Rights Act×20

CICP×20

Coverage of Accelerated Approval Products×20

Patient Cost-Sharing and Smoothing×20

PBM Reform×20

Prescription Drug User Fee Act×20

PROTECT 340B Act×20

Accelerated Approval Artificial Intelligence×19

Access to Innovative Treatments Act×19

Countermeasures Injury Compensation Program×19

COVID-19 Pricing Related Provisions×19

SUSTAIN 340B Act×19

TRIPS Waiver×19

Vaccine Safety and Quality×19

VICP Loopholes×19

Accredited Investor Definition Review Act×18

Bayh-Dole Act×18

CFIUS and Foreign Investment Drug Pricing×18

Countermeasure Injury Compensation Fund Amendment Act×18

Drug Patenting×18

Encouraging Innovation Benefit Design to Lower Costs for Seniors Act×18

Equal Opportunity for All Investors Act×18

Expensing of R&D Expenditures×18

Foreign Drug Data Protection Laws×18

Genetic Resources, and Associated Traditional Knowledge×18

MCM PRV Program Reauthorization×18

Medicaid Drug Rebate Program×18

Pandemic Flu×18

Reimbursement Cell & Gene Therapy×18

Section 101 Modernization×18

Vaccine and Antimicrobial Resistance Product Development and Incentives×18

WHO Pandemic Preparedness Accord Biosimilars×18

340B Drug Discount Program×17

Accredited Investor Definition×17

Act 3.0 Medicaid×17

Biosimilars Red Tape Elimination Act×17

DRUG Act×17

FDA Hiring Flexibility×17

FDA Modernization×17

Influenza Planning & Response×17

Innovation in Pediatric Drugs Act×17

MCM R&D Incentives×17

Pharmacy Benefit Managers Artificial Intelligence×17

Project Bioshield×17

Retaining Access and Restoring Exclusivity×17

Section 232×17

State Strategic Stockpile Act×17

Step Therapy×17

Treaty on Intellectual Property×17

Vaccine Access & Compensation×17

Vaccine Quality Measure×17

Vaccine Safety×17

Accelerated Approval Antimicrobial Resistance Artificial Intelligence×16

Advise and advocate on client's behalf regarding ongoing public policy×16

Capital Formation Incentives×16

Climate Issues & impact on the agriculture and food sectors×16

Compounded Medicines×16

Decentralized Clinical Trials Drug Evaluation and Review×16

Disease X Act×16

Diversity & Inclusion×16

Fair Investment Opportunities for Professional Experts Act×16

Funding for Medical Countermeasures×16

Gain of function×16

Generic Drug Application Review Reforms×16

Generic Drug Entry×16

Incentives for Generic Entry Issues×16

Patenting of Biological Inventions×16

Pharmacy Benefit Managers×16

Precision Medicine Initiative Reimbursement and Coverage of Innovative Products×16

Reference Pricing in Drug Reimbursement×16

SAFE Risky Research Act×16

VICP/CICP Capital Formation Incentives×16

World Intellectual Property Office×16

340B Drug Pricing Program×15

Access to Innovative Treatments×15

BIOSECURE Act/S×15

Cameron's Law Pandemic Preparedness Research & Development Tax Credit Reforms×15

Compounding Pharmacies×15

Contract Manufacturing Ecosystem in the United States×15

Coverage and Reimbursement×15

Drug patents and patent reporting requirements×15

Medicare and Medicaid payment and coverage issues×15

Most Favored Nation in Medicaid×15

NSCEB Recommendations Opioid Crisis×15

PASTEUR ACT×15

Patent Tax/fees×15

Public Float Threshold Update Small Business Innovation Research×15

Section 317 Immunization Program×15

Tariffs Foreign Agricultural Biotechnology Laws and Regulations×15

Vaccine Injury Compensation Program 340B Drug Discount Program×15

Vaccines and Infectious Diseases 340B Drug Discount Program×15

VICP/CICP Antimicrobial Resistance Biodefense Research×15

White House National Biodefense Strategy×15

WHO Pandemic Preparedness Accord Pandemic Preparedness×15

28 U.S.C. 1498×14

Capital Market Enhancements×14

CDC Reform×14

China Synthetic Biotech×14

CMMI Models: GLOBE and GUARD×14

Compulsory Licensing×14

Consumer Data Privacy and Security Act×14

Diagnostics and Personalized Medicine Regulation and Oversight×14

FDA Hiring Staffing Drug Importation Drug Manufacturing×14

Incentives for Domestics Manufacturing Orphan Drug Issues×14

INNOVATE Act×14

Mikaela Naylon Give Kids a Chance Act×14

NSC/OSTP priorities×14

Nucleic acid synthesis security and biotechnology governance×14

Patent and copyright cases Data Privacy×14

Patent Reform×14

PDUFA VII Implementation×14

PDUFA VIII Negotiations Drug Importation Drug Manufacturing×14

PTAB Reform×14

Purple Book Draft×14

R&D Payroll Credit Vaccines and Infectious Disease×14

Rare Disease Pilot Program Reimbursement and Coverage of Innovative Products×14

Tariffs Foreign Drug Data Protection Laws Medicaid×14

US-China IP Provisions United Nations World Trade Organization×14

VICP/CICP Biodefense Research×14

Monoclonal Antibody Coverage and Utilization×13

Incentives for Sustainable Aviation Fuels×10

FDA Approvals×9

Guidance, & Regulations×9

WHO Pandemic Preparedness Accord×9

Agricultural Biorefinery Innovation and Opportunity×8

Biomass Crop Assistance, and Biorefineries×8

Farm Bill Reauthorization×8

Food and Drug Administration, and Related Agencies Appropriations Act×8

Rural Development×8

SUPPORT Act×8

American Innovation and R&D Competitiveness Act×7

Gene Editing×7

Genetically Engineered×7

MCM PRV Program×7

Prohibiting Adversarial Patents Act×7

Small Entity Update Act×7

ASPR×6

Bill to address patent thickets×6

Efficient Science-Based Review of Biotech Products×6

Expanding Access to Capital Act×6

HELP Copays Act×6

HHS Reorganization×6

Patent Eligibility Restoration Act×6

Pediatric Priority Review Voucher Program×6

Prescription Drug Price Relief Act×6

Safe, and Secure American Bioeconomy×6

Sustainable Aviation Fuels Tax Credit×6

Temporarily Refundable R&D Credit×6

Tropical Disease Priority Review Voucher×6

Administration Rebate Rule×5

American Innovation Act×5

BARDA×5

Farm to Fly Act×5

National Institute of Health×5

Non-Opioid Analgesics×5

Orphan Drug Issues×5

Patent Thickets×5

Protected Classes×5

340B Accountability Act×4

Biofuels and SAF×4

China Patent Reform×4

Creating Hope Reauthorization×4

Decentralized Clinical Trials×4

Drug pricing and supply chain issues×4

Emerging New Threats and×4

Executive Order on Achieving Efficiency Through State and Local Preparedness×4

Fair Prescription Drug Prices for Americans Act×4

Farm Bill×4

FDA Hiring Flexibility Drug Importation Drug Manufacturing×4

Federal proposals and policies×4

Finding Orphan-Disease Remedies with Antifungal Research and Development×4

FTC Orange Book Delisting Initiative×4

FY 2026 Appropriations Funding for Antimicrobial Resistance×4

Impacting the innovative biotechnology industry, including: health care policies×4

International Consistency of Regulations×4

IRA Tax Credits×4

Lower Costs×4

Medicare payment, coverage, and reimbursement×4

National Defense Authorization Act 2026×4

Protecting Americans Data from Foreign Adversaries Act×4

VICP×4

ASPR FY 2026 Appropriations for Specific Issues×3

BSUFA Negotiations×3

China Synthetic Biotech Tariffs Trade Relations×3

Climate Change×3

Compounded Medicines Drug Patenting×3

Coverage and Reimbursement Orphan Drug Issues×3

COVID-19 Lessons Learned×3

EPA proposed revisions to regulations×3

ETHIC Act×3

Food & Ag National Security×3

Global Fairness in Drug Pricing Act×3

House GOP RFI on Data Privacy×3

MCM PRV×3

Medical Countermeasures PRV Reauthorization×3

Medicare Negotiation and Competitive Licensing Act×3

Orphan Drug Tax Credit Pandemic Preparedness×3

Patent Litigation Reform×3

Pioneering Antimicrobial Subscriptions to End Upsurging Resistance×3

PPRV×3

PTO Proposed Rules on Terminal Disclaimer Practice×3

Reasonable Pricing Clauses in BARDA Contracts×3

USMCA Review×3

Amended Definition of Smaller Reporting Company×2

AMMTO×2

APHIS×2

Avian Flu×2

B5 Coalition on Supply Chain Resiliency×2

Banking Policy×2

BETA×2

Biodefense Research×2

Biomanufacturing and Jobs Act×2

Biomass Programs×2

Biosecurity Infrastructure for Operational×2

Biotechnology and Agriculture Trade Program×2

Cell & Gene Therapy×2

Dept of Commerce Patent Valuation Fee Proposal×2

Drug Evaluation and Review×2

Drug Importation Drug Manufacturing×2

EU Ag-Biotech Policies×2

Family Vaccine Protection Act×2

Farm Bill Programs Energy Title IX×2

Fuels & Metrics×2

Funding for Biodefense/Biomedical/Emergency Preparedness Research×2

Funding for Biofuels×2

General tax issues×2

Improving Data Accessibility Through Advancements×2

Infectious Disease Therapies Research and Innovation Act×2

International Consistency of Regulation for Gene Edited Products×2

Inventor Diversity for Economic Advancement×2

Investment Tax Credit×2

Korea Biotechnology Regulations×2

Medicaid Drug Rebate Program Rule×2

MINI Act×2

More Cures Act×2

More Transparency Act×2

Most Favored Nation Foreign Drug Data Protection Laws×2

National Institutes of Health FY 2026 Appropriations for Specific Issues×2

NDAA×2

Net Operating Loss×2

Net Operating Loss Advance Refunds×2

NextGen Aircraft Technology×2

Office of Biopesticides and Pollution Prevention Division×2

Optimizing Research Progress Hope And New Cures Act×2

Orange Book Listing×2

Project Bio Shield×2

Protecting Patient Access to Cancer and Therapies×2

Putting Investors First Act×2

R&D Payroll Credit×2

Reasonable Pricing Clause Compulsory Licensing Data Privacy×2

Small Issuer Exemption Small Business Innovation Research×2

Stronger Patents Act×2

U.S. policies×2

US China IP Provisions×2

USDA×2

Vaccines and Infectious Disease×2

VICP CICP×2

WHO Pandemic Preparedness Accord World Intellectual Property Office×2

World Health Organization×2

340B ACCESS Act×1

340B Rebate Pilot Program×1

Accelerated Approval Access to non-human Primates×1

Accredited Investor Certification Sarbanes Oxley Section 404×1

Adjusting the well-known seasoned issues×1

Administrative Rebate Rule×1

Ag-Biotech Provisions×1

American Pandemic Preparedness Plan×1

Avian Flu Farm Bill×1

BARDA FY 2026 Appropriations for Specific Issues×1

Bilateral Trade Negotiations×1

Bioenergy Technology Office×1

Biologics Competition Act×1

Capital Market Enhancements Small Business Innovation Research×1

Carbo Capture Utilization Parity Capital Formation Incentives×1

CICP Funding for FDA×1

Climate Change Data Privacy×1

Clinical Trial Diversity×1

Clinical Trial Diversity Drug Evaluation and Review×1

Clinical Trial Modernization×1

CMMI Models×1

Compounding & Counterfeit Medicines Drug Patenting×1

Counterfeit Drug Monitoring Drug Pricing×1

Definition to allow for a larger financing round using×1

Department of Energy×1

Department of Transportation×1

Dept of Energy×1

Dept of Interior×1

Dept of Transportation×1

DOE and USDA Interagency Research Act×1

Drug Manufacturing×1

Drug Rebate Program Rule×1

Education on global supply chain management in biotechnology×1

Efforts to expand the Bio Economy & Bio Manufacturing×1

End Price Gauging for Medications Act×1

Enhanced Access to Affordable Medicines Act×1

Environment and Energy R&D×1

Environmental Energy R&D×1

EPA Regulatory Approach to Gene Editing×1

FDA Hiring Flexibility Drug Manufacturing×1

FDA Proposed guidance on Gene Editing×1

FDA Reform×1

Fighting Climate Change through Biotechnology Innovation Funding for Biofuels×1

Food and Ag Organization×1

Foreign Animal Disease Efforts to expand the Bio Economy & Bio Manufacturing×1

Foreign Animal Disease Farm Bill×1

Foreign Drug Data Protection Law×1

Funding for Antimicrobial Resistance×1

Funding for Renewable Materials/Bio-based Products×1

Funding for Womens Health Research International Reference Pricing Medicaid×1

FY 2026 Appropriations Clinical Trial Data in China Data Privacy×1

FY 2026 Appropriations Data Privacy×1

FY 2026 Appropriations Genetically Engineered×1

FY 2026 Appropriations International Reference Pricing Issues×1

FY 2026 Appropriations Pandemic Preparedness×1

FY2025 Appropriations×1

General Artificial Intelligence×1

General Cell & Gene Therapy×1

General Climate Change×1

General Diversity & Inclusion×1

General Drug Evaluation and Review×1

General Pandemic Preparedness Renewable Chemicals/Bio-based Products×1

HHS Reorganization CDC Reform×1

HHS Reorganization Pandemic Preparedness×1

Impacting Emerging Companies×1

Impacting Emerging Companies Capital Formation Incentives×1

Innovation and Pediatric Drugs Act×1

Intellectual Property Enforcement×1

Intellectual Property International Enforcement×1

International Reference Pricing Foreign Drug Data Protection Laws×1

Invent Here×1

IP Provisions World Health Organization×1

JOBS Act 4.0×1

Make Here Act×1

March-In Rights×1

March-In Rights Compulsory Licensing Data Privacy×1

March-In Rights Data Privacy×1

Market Liquidity Proposals×1

MCM PRV Program CDC Reform×1

Medical Supply Chain Resiliency Act×1

Mergers and Acquisitions Reform×1

Mexico Decree Banning Genetically Modified Corn Funding for the USDA×1

Mitigating Climate Change through Biotechnology Innovation Funding for Biofuels×1

Most Favored Nation Foreign Agricultural Biotechnology Laws and Regulations×1

Most Favored Nation Pricing×1

Most Favored Nation Pricing Opioid Crisis×1

National Institute of Health FY 2026 Appropriations for Specific Issues×1

Patent Tax/fees Foreign Drug Data Protection Law×1

Patent Thickets Drug Pricing×1

Patentability of AI-Aided inventions Bayh-Dole Act/Tech Transfer×1

PBN Reform×1

PDUFA×1

PDUFA VIII Negotiations×1

Prescription Drug Pricing for the People Act×1

Program & Oversight×1

Protecting Consumer Access to Generic Drugs Act×1

Public Float Threshold Update×1

Public Float Threshold Update Sarbanes Oxley Section 404×1

R&D Payroll Credit Vaccine Injury Compensation Program×1

Rare Disease Pilot Program Pandemic Preparedness×1

Reg 53963 Patenting of Biological Inventions×1

Regulatory Burden Capital Formation Incentives×1

Regulatory Harmonization Funding for Antimicrobial Resistance×1

Regulatory Harmonization Medicaid×1

Regulatory Treatment of Biostimulants United States-Mexico-Canada Agreement×1

Regulatory Treatment of Gene Edited Products×1

Reimbursement and Coverage of Innovative Products×1

Reimbursement Cell & Gene Therapy Data Privacy×1

Renewable Chemicals/Bio-based Products Renewable Chemicals/Bio-based Products×1

Renewable Materials/BIO-based Products×1

RESTORE Patent Rights Act×1

SEC Small Business Forum×1

Section 317 Immunization Program 340B Drug Discount Program×1

Skinny Labels×1

Small Business Capital Formation Enhancement Act×1

SMART Prices Act×1

Synthetic Biotech Pharmaceutical and Ag Biotech Tariffs US-China Trade Agreement×1

Synthetic Nucleic Acid Synthesis Screening×1

Tax Relief for American Families and Workers Act×1

Title 35 to Address Infringements of Patents Claiming Biological Products×1

United Nations×1

US-China Ag-Biotech Provisions×1

USDA Avian Flu×1

USDA FY 2026 Appropriations for Specific Issues×1

USDA Regulatory Approach to Gene Editing Interagency Coordination×1

User Fees Funding for Health Resources and Services Administration×1

USPTO Request for Comments: Experimental Use Defense 89 Fed×1

Vaccine Access×1

Vaccines for Children Program×1

VICP Biofuels and SAF×1

Womens Health Research Pandemic Preparedness×1

Word Health Organization×1

World Trade Organization×1

Bills in Play

Bills referenced in this org's LD-2 filing text. Frequency = how many activities reference each.

112 mentions

94 mentions

59 mentions

47 mentions

46 mentions

46 mentions

44 mentions

44 mentions

43 mentions

42 mentions

37 mentions

32 mentions

31 mentions

31 mentions

31 mentions

30 mentions

30 mentions

28 mentions

28 mentions

28 mentions

Show all 58 bills (+38 more) ▾

28 mentions

21 mentions

17 mentions

16 mentions

16 mentions

16 mentions

16 mentions

16 mentions

15 mentions

15 mentions

15 mentions

14 mentions

14 mentions

14 mentions

14 mentions

14 mentions

14 mentions

14 mentions

14 mentions

14 mentions

14 mentions

14 mentions

3 mentions

3 mentions

3 mentions

3 mentions

3 mentions

2 mentions

2 mentions

2 mentions

2 mentions

2 mentions

2 mentions

1 mention

1 mention

1 mention

1 mention

1 mention

Lobbyists on Record

RAGHAV AGGARWAL · Bgr Government Affairsformer Health Insurance Specialist, CMS; Senior Health…

DON ANDRES · Bgr Government Affairsformer COS, Rep Norma Torres; COS, LD, Rep Jesus Chuy …

JOEL BAILEY · Bgr Government Affairsformer COS Rep. Panetta; LD Rep. Ashford; LD Rep. Math…

BRETT BAKER · The Nickles Group, LLCformer U.S. Senate Committee on Finance (Senators Crap…

GORDON BATES · Akin Gump Strauss Hauer & Feldformer CoS, Sen. McConnell, 2000-02; Legal Cnsl, Sen. …

TARA BILLINGSLEY · Jim Massie & Partners, LLCformer Special Assistant to the President and Senate L…

JENNIFER BROWN · Bgr Government Affairsformer Bnk. Coun. Ldr. Schumer; Tax Coun. Sen. Menende…

RICHARD BURR · Dla Piper LLP (US)former U.S. Senator

CAITLIN CANTER · Avoq, LLCformer Deputy Chief of Staff, Legislative Assistant, L…

ADAM CARASSO · Capitol Counsel LLCformer Senior Tax and Economic Advisor, Senate Finance…

JEFFREY CARROLL · Capitol Counsel LLCformer Staff Director House Energy and Commerce Commit…

BLAKE CENTER · Valcour LLCformer Intern, Sen. Bob Corker; Staff Assistant, Legis…

+ 64 more lobbyists on record